Example: Heart Attack

Search clinical trials for: Dacarbazine

Total 193 results

NCT04397770

Not yet recruiting

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

Conditions: Melanoma
NCT04307277

Not yet recruiting

Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Grade 1 or 2 Soft Tissue Sarcoma

Conditions: Soft Tissue Sarcoma
NCT04225390

Not yet recruiting

Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy

Conditions: Immunotherapy
NCT04221035

Recruiting

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Conditions: High-Risk Neuroblastoma
NCT04200040

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients

Conditions: Melanoma (Skin)
NCT04067037

Recruiting

Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

Conditions: Classical Hodgkin Lymphoma
NCT03907488

Recruiting

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Conditions: Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma; Ann Arbor Stage IIIA Hodgkin Lymphoma; Ann Arbor Stage IIIB Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma; Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma; Ann Arbor Stage IVA Hodgkin Lymphoma; Ann Arbor Stage IVB Hodgkin Lymphoma; Classic Hodgkin Lymphoma; Lymphocyte-Rich Classic Hodgkin Lymphoma
NCT03761095

Recruiting

A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

Conditions: Leiomyosarcoma
NCT03755804

Recruiting

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Conditions: Hodgkin Lymphoma
NCT03712202

Recruiting

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Conditions: Ann Arbor Stage I Hodgkin Lymphoma; Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma; Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma; Ann Arbor Stage IA Hodgkin Lymphoma; Ann Arbor Stage IB Hodgkin Lymphoma; Ann Arbor Stage II Hodgkin Lymphoma; Ann Arbor Stage IIA Hodgkin Lymphoma; Ann Arbor Stage IIB Hodgkin Lymphoma; Classic Hodgkin Lymphoma; Lymphocyte-Rich Classic Hodgkin Lymphoma; Ann Arbor Stage I Lymphocyte-Depleted Classic HL; Ann Arbor Stage II Lymphocyte-Depleted Classic HL; Ann Arbor Stage II Mixed Cellularity Classic HL; Ann Arbor Stage II Nodular Sclerosis Classic HL
NCT03646123

Recruiting

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Conditions: Hodgkin Lymphoma
NCT03527628

Recruiting

OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy

Conditions: Classical Hodgkin Lymphoma; Hodgkin Lymphoma (Category); Hodgkin Disease; Hodgkin Lymphoma
NCT03517137

Recruiting

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

Conditions: Advanced Hodgkin Lymphoma
NCT03435302

Unknown status

HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Conditions: Melanoma
NCT03430297

Recruiting

A Phase Ⅲ Study to Investigate Toripalimab Versus Dacarbazine as the First Line Therapy for Unresectable or Metastatic Melanoma

Conditions: Metastatic Melanoma; Unresectable Melanoma
NCT03407144

Recruiting

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

Conditions: Hodgkin Lymphoma
NCT03342300

Withdrawn

Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma

Conditions: Progression-free Survival; Overall Survival; Toxicity
NCT03331341

Recruiting

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

Conditions: Classical Hodgkin Lymphoma
NCT03279601

Recruiting

Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor

Conditions: Neuroendocrine Tumors
NCT03233347

Recruiting

Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Conditions: Ann Arbor Stage I Hodgkin Lymphoma; Ann Arbor Stage IA Hodgkin Lymphoma; Ann Arbor Stage IB Hodgkin Lymphoma; Ann Arbor Stage II Hodgkin Lymphoma; Ann Arbor Stage IIA Hodgkin Lymphoma; Ann Arbor Stage IIB Hodgkin Lymphoma; Classic Hodgkin Lymphoma
NCT03226249

Active, not recruiting

PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma

Conditions: Classical Hodgkin Lymphoma; Lymphocyte-Depleted Classical Hodgkin Lymphoma; Lymphocyte-Rich Classical Hodgkin Lymphoma; Mixed Cellularity Classical Hodgkin Lymphoma; Nodular Sclerosis Classical Hodgkin Lymphoma
NCT03217097

Recruiting

MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents

Conditions: Neuroendocrine Tumors
NCT03159897

Recruiting

FIL Study on ABVD DD-DI as Upfront Therapy in HL.

Conditions: Hodgkin Lymphoma
NCT03095079

Unknown status

Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma

Conditions: Melanoma
NCT03070392

Active, not recruiting

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Conditions: Uveal Melanoma
NCT03033914

Recruiting

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Conditions: Hodgkin Lymphoma
NCT03023124

Recruiting

Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor

Conditions: Solitary Fibrous Tumors
NCT03016819

Recruiting

A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

Conditions: Alveolar Soft Part Sarcoma; Leiomyosarcoma; Synovial Sarcoma; Soft-Tissue Sarcoma
NCT03004833

Active, not recruiting

Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

Conditions: Classical Hodgkin Lymphoma
NCT02994498

Not yet recruiting

Safety and Efficacy of DCB-BO1301 in Advanced Melanoma

Conditions: Advanced Melanoma
NCT02979522

Active, not recruiting

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Conditions: Hodgkin Disease
NCT02800447

Unknown status

Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol

Conditions: Advanced Hodgkin's Lymphoma
NCT02797717

Recruiting

Treatment for Classical Hodgkin Lymphoma in Children and Adolescents

Conditions: Classical Hodgkins Lymphoma in Children and Adolescents.
NCT02788201

Completed

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

Conditions: Urothelial Carcinoma; Bladder Cancer; Urinary Bladder Neoplasms
NCT02758717

Active, not recruiting

Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

Conditions: Ann Arbor Stage IB Hodgkin Lymphoma; Ann Arbor Stage II Hodgkin Lymphoma; Ann Arbor Stage IIA Hodgkin Lymphoma; Ann Arbor Stage IIB Hodgkin Lymphoma; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage IIIA Hodgkin Lymphoma; Ann Arbor Stage IIIB Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IVA Hodgkin Lymphoma; Ann Arbor Stage IVB Hodgkin Lymphoma; Classic Hodgkin Lymphoma
NCT02684708

Recruiting

Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

Conditions: Classical Hodgkin Lymphoma
NCT02661503

Recruiting

HD21 for Advanced Stages

Conditions: Classical Hodgkin Lymphoma
NCT02545075

Completed

A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine

Conditions: Melanoma
NCT02526823

Recruiting

Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma

Conditions: Lymphoma, Non-Hodgkin;Hodgkin Disease
NCT02505269

Completed

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Conditions: Hodgkin Lymphoma
NCT02501551

Recruiting

Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy

Conditions: Melanoma
NCT02298257

Active, not recruiting

A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma

Conditions: HIV Infection; HIV-associated Hodgkin Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage IV Adult Hodgkin Lymphoma
NCT02292979

Active, not recruiting

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.

Conditions: Hodgkin Lymphoma
NCT02288897

Terminated

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Conditions: Cutaneous Melanoma
NCT02275598

Unknown status

Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma

Conditions: Hodgkin Lymphoma
NCT02247869

Completed

Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma

Conditions: Hodgkin Lymphoma
NCT02190838

Terminated

Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma

Conditions: Melanoma
NCT02181738

Active, not recruiting

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Conditions: Hodgkin Disease
NCT02076646

Unknown status

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Conditions: Metastatic Melanoma Stage IV
NCT02049905

Completed

Phase 3 Study to Treat Patients With Soft Tissue Sarcomas

Conditions: Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma

Search clinical trials for: Dacarbazine

Recent CRA jobs

Medical Comm Writer 1

Applications Administrator(SAS Grid)

Associate Project Manager - GOV

Associate CTM

Assoc Scientist- CSD

Pharmacovigilance Manager

Lab Supervisor - Client dedicated

Scientist, Cell and Gene Therapy – (on-site Stevenage, UK - 18 month contract)

Senior Scientist - Biopharmaceutical Stability Testing

Associate Scientist - PCC